{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T07:54:59Z","timestamp":1703577299506},"reference-count":32,"publisher":"Consilium Medicum","issue":"12","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Subjects and methods. A total of 61 patients (41 with ET and 20 with PV) were examined. Prior to study enrolment, 44 (72%) patients with ET or PV received one or other therapy (aspirin was not taken into account). The mean Jak2V617F mutant allele at baseline was 23% (6\u201454%) in the patients with ET and 40% (11\u201488%) in those with PV. The median time from diagnosis to enrollment was 49 months. Results. The paper presents the clinical and molecular findings of long-term INF-\u03b1 therapy in patients with ET or PV. The median follow-up was 52 months. Recombinant IFN-\u03b12 showed its ability to induce complete hematologic remission (ET (76%), PV (70%)) and a complete molecular response. 22 (69%) out of 32 patients were noted to have a smaller number of cells with the Jak2V617F mutation. In the patients with PV and in those with ET, the relative reduction in the proportion of cells with the Jak2V617F mutant gene averaged 85% and 56% of the baseline values, respectively. There was a reduction in the proportion of cells expressing the Jak2V617F mutation in both the ET (from 12 to 2.2%; p=0.001) and PV (from 32.7% to 3.2%) groups (\u0440=0.001). Ten (31%) patients achieved a deep molecular remission (\u22642% Jak2V617F allele); among them, 5 patients were not found to have Jak2V617F mutation. The obtained molecular response remained in 7 of the 10 patients untreated for 11 to 86 months. The long-term treatment with IFN-\u03b1 led to normalization of the morphological pattern of bone marrow in 5 of the 7 PV or ET patients. Conclusion. Significant molecular remissions achieved by therapy with recombinant interferon-\u03b12 confirm the appropriateness of this treatment option in in the majority of patients with ET or PV.<\/jats:p>","DOI":"10.17116\/terarkh2016881269-77","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T14:59:26Z","timestamp":1485183566000},"page":"69-77","source":"Crossref","is-referenced-by-count":1,"title":["Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera"],"prefix":"10.26442","volume":"88","author":[{"given":"M A","family":"Sokolova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A G","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Melikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A B","family":"Sudarikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Treglazova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O A","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E G","family":"Gemdzhian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A \u041e","family":"Abdullaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Kovrigina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Misyurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu V","family":"Pliskunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V L","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T N","family":"Moiseeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.10"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"ref4","unstructured":"\u0425\u043e\u0440\u043e\u0448\u043a\u043e \u041d.\u0414., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0416\u0443\u0440\u0430\u0432\u043b\u0435\u0432 \u0412.\u0421., \u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430 \u041c.\u0410. , \u0421\u0435\u043c\u0435\u043d\u043e\u0432\u0430 \u0415.\u0410., \u0426\u0432\u0435\u0442\u0430\u0435\u0432\u0430 \u041d.\u0412., \u041a\u043e\u043b\u043f\u0438\u043a\u043e\u0432\u0430 \u041b.\u0410. \u00ab\u041c\u0435\u0441\u0442\u043e \u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d\u0430-\u0430 \u0432 \u043a\u043e\u0440\u0440\u0435\u043a\u0446\u0438\u0438 \u0433\u0438\u043f\u0435\u0440\u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u043e\u0437\u0430 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c\u0438 \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u043c\u0438 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f\u043c\u0438\u00bb. \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 1999;4:43-45."},{"key":"ref5","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00b4an A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-175."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23018"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009860"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24440"},{"key":"ref10","unstructured":"\u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c., \u0417\u0430\u0440\u0438\u0446\u043a\u0438\u0439 \u0410.\u042e., \u0410\u0444\u0430\u043d\u0430\u0441\u044c\u0435\u0432 \u0411.\u0412., \u0428\u0443\u0432\u0430\u0435\u0432 \u0412.\u0410., \u041b\u043e\u043c\u0430\u0438\u0430 \u0415.\u0413., \u041c\u043e\u0440\u043e\u0437\u043e\u0432\u0430 \u0415.\u0412., \u0411\u0430\u0439\u043a\u043e\u0432 \u0412.\u0412., \u0413\u043e\u043b\u0435\u043d\u043a\u043e\u0432 \u0410.\u041a., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d., \u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430 \u041c.\u0410., \u041a\u043e\u0432\u0440\u0438\u0433\u0438\u043d\u0430 \u0410.\u041c., \u041c\u0430\u0440\u0442\u044b\u043d\u043a\u0435\u0432\u0438\u0447 \u0418.\u0421., \u0413\u0440\u0438\u0446\u0430\u0435\u0432 \u0421.\u0412., \u0421\u0443\u0434\u0430\u0440\u0438\u043a\u043e\u0432 \u0410.\u0411., \u0421\u0443\u0445\u0430\u043d\u043e\u0432\u0430 \u0413.\u0410., \u0418\u0432\u0430\u043d\u043e\u0432\u0430 \u0412.\u041b., \u041a\u0430\u043f\u043b\u0430\u043d\u043e\u0432 \u041a.\u0414., \u041a\u043e\u043d\u0441\u0442\u0430\u043d\u0442\u0438\u043d\u043e\u0432\u0430 \u0422.\u0421. ,\u041f\u043e\u0441\u043f\u0435\u043b\u043e\u0432\u0430 \u0422.\u0418., \u0410\u0433\u0435\u0435\u0432\u0430 \u0422.\u0410., \u0428\u0430\u0442\u043e\u0445\u0438\u043d \u042e.\u0412., \u0421\u0430\u0432\u0447\u0435\u043d\u043a\u043e \u0412.\u0413. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 Ph-\u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439 (\u0438\u0441\u0442\u0438\u043d\u043d\u0430\u044f \u043f\u043e\u043b\u0438\u0446\u0438\u0442\u0435\u043c\u0438\u044f, \u044d\u0441\u0441\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u0430\u044f \u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u0435\u043c\u0438\u044f, \u043f\u0435\u0440\u0432\u0438\u0447\u043d\u044b\u0439 \u043c\u0438\u0435\u043b\u043e\u0444\u0438\u0431\u0440\u043e\u0437). \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0438\u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2014;59(4):31-56."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standart for oncology clinical trials Journal Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004. 22(14S(July 15 Supplement)): p.1","DOI":"10.1200\/jco.2004.22.14_suppl.6098"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176818"},{"key":"ref14","unstructured":"\u0410\u0431\u0434\u0443\u043b\u043b\u0430\u0435\u0432 \u0410.\u041e., \u0413\u043b\u0438\u043d\u0449\u0438\u043a\u043e\u0432\u0430 \u041e. \u0410. \u0421\u0443\u0441\u043b\u043e\u0432\u0430 \u0421. \u0410. \u0428\u0430\u0434\u0438\u0435\u0432\u0430 \u041d. \u0425. \u041a\u043e\u043b\u043e\u0441\u043e\u0432\u0430 \u041b. \u042e. \u041c\u0435\u0449\u0435\u0440\u044f\u043a\u043e\u0432\u0430 \u041b. \u041c. \u0412\u0430\u0445\u0440\u0443\u0448\u0435\u0432\u0430 \u041c. \u0412. \u0421\u0443\u0434\u0430\u0440\u0438\u043a\u043e\u0432 \u0410. \u0411. \u041a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043e\u0446\u0435\u043d\u043a\u0430 \u043c\u0443\u0442\u0430\u0446\u0438\u0438 v617f \u0433\u0435\u043d\u0430 jak2 \u043f\u0440\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f\u0445. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043b\u0430\u0431\u043e\u0440\u0430\u0442\u043e\u0440\u043d\u0430\u044f \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430. 2012;7:24-28."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5463"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03287.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-942762"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.69"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0498-4"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053348"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404861"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319-2327. doi:NOT","DOI":"10.1182\/blood.V89.7.2319"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12473408860587"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191544"},{"key":"ref26","unstructured":"\u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430 \u041c.\u0410., \u0426\u0432\u0435\u0442\u0430\u0435\u0432\u0430 \u041d.\u0412., \u0421\u0443\u0445\u0430\u043d\u043e\u0432\u0430 \u0413.\u0410., \u0412\u0430\u0441\u0438\u043b\u044c\u0435\u0432 \u0421.\u0410., \u0421\u0430\u043d\u0430\u0442\u043a\u043e \u041c.\u0414., \u0425\u043e\u0440\u043e\u0448\u043a\u043e \u041d.\u0414. \u0420\u0430\u0437\u0432\u0438\u0442\u0438\u0435 \u0441\u0438\u043d\u0434\u0440\u043e\u043c\u0430 \u0411\u0430\u0434\u0434\u0430\u2014\u041a\u0438\u0430\u0440\u0438 \u0443 \u043c\u043e\u043b\u043e\u0434\u043e\u0439 \u0431\u043e\u043b\u044c\u043d\u043e\u0439 \u0432 \u0434\u0435\u0431\u044e\u0442\u0435 \u043f\u0435\u0440\u0432\u0438\u0447\u043d\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u0444\u0438\u0431\u0440\u043e\u0437\u0430 (\u0441\u0443\u0431\u043b\u0435\u0439\u043a\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u0437\u0430): \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043d\u0430\u0431\u043b\u044e\u0434\u0435\u043d\u0438\u0435. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. \u0424\u0443\u043d\u0434\u0430\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u044b\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0438 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0430. 2010;1(3):"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236596"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22026"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235119"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.012"},{"key":"ref32","unstructured":"\u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430 \u041c.\u0410., \u0425\u043e\u0440\u043e\u0448\u043a\u043e \u041d.\u0414., \u0414\u043c\u0438\u0442\u0440\u0438\u0435\u0432\u0430 \u041c.\u0413., \u0416\u0443\u0440\u0430\u0432\u043b\u0435\u0432 \u0412.\u0421., \u0421\u0430\u0433\u0434\u0438\u0435\u0432\u0430 \u041d.\u0428., \u0415\u0433\u043e\u0440\u043e\u0432\u0430 \u041c.\u041e., \u041c\u043e\u0438\u0441\u0435\u0435\u0432\u0430 \u041d.\u0421., \u041d\u0430\u0440\u0435\u0439\u043a\u043e \u041c.\u0412., \u0413\u0435\u043c\u0434\u0436\u044f\u043d \u042d.\u0413., \u0421\u0430\u0445\u0438\u0431\u043e\u0432 \u042f.\u0414. \u041e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043f\u043e\u0434\u0445\u043e\u0434\u0430 \u043a \u044d\u0440\u0438\u0442\u0440\u043e\u0446\u0438\u0442\u043e\u0437\u0430\u043c \u0440\u0430\u0437\u043b\u0438\u0447\u043d\u043e\u0433\u043e \u043f\u0440\u043e\u0438\u0441\u0445\u043e\u0436\u0434\u0435\u043d\u0438\u044f. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2012;84(4):29-35."}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32095\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:16:17Z","timestamp":1658502977000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/32095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,15]]}},"URL":"https:\/\/doi.org\/10.17116\/terarkh2016881269-77","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}